View ValuationHK inno.N 将来の成長Future 基準チェック /16HK inno.N利益と収益がそれぞれ年間17.8%と6.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に5.8% 17.9%なると予測されています。主要情報17.8%収益成長率17.88%EPS成長率Pharmaceuticals 収益成長21.8%収益成長率6.5%将来の株主資本利益率5.80%アナリストカバレッジGood最終更新日20 Jul 2026今後の成長に関する最新情報Major Estimate Revision • May 03Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from ₩3,012 to ₩2,574 per share. Revenue forecast steady at ₩917.8m. Net income forecast to grow 11% next year vs 17% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩53,750 unchanged from last update. Share price was steady at ₩39,150 over the past week.Major Estimate Revision • Apr 14Consensus EPS estimates increase by 19%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩2,573 to ₩3,050. Revenue forecast steady at ₩918.9m. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩53,750. Share price fell 4.4% to ₩35,150 over the past week.Major Estimate Revision • Apr 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩896.1m to ₩865.0m. EPS estimate also fell from ₩1,648 per share to ₩1,326 per share. Net income forecast to shrink 4.9% next year vs 39% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target broadly unchanged at ₩49,857. Share price was steady at ₩35,250 over the past week.Price Target Changed • Nov 16Price target decreased to ₩52,500Down from ₩58,000, the current price target is an average from 8 analysts. New target price is 38% above last closing price of ₩38,100. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,458 for next year compared to ₩849 last year.Major Estimate Revision • May 13Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩831.5m to ₩820.0m. EPS estimate also fell from ₩1,423 per share to ₩1,277 per share. Net income forecast to grow 49% next year vs 14% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩58,000 to ₩53,800. Share price was steady at ₩39,450 over the past week.すべての更新を表示Recent updatesお知らせ • Apr 23HK inno.N Corporation to Report Q1, 2026 Results on Apr 28, 2026HK inno.N Corporation announced that they will report Q1, 2026 results on Apr 28, 2026Board Change • Apr 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Chairman of the Board Yeo-Won Son was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Declared Dividend • Mar 12Dividend of ₩410 announcedShareholders will receive a dividend of ₩410. Ex-date: 25th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.8%, which is lower than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 2.3% per year over the past 4 years and payments have been stable during that time.お知らせ • Mar 12HK inno.N Corporation, Annual General Meeting, Mar 26, 2026HK inno.N Corporation, Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 178, osongsaengmyeong-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Koreaお知らせ • Feb 11HK inno.N Corporation to Report Q4, 2025 Results on Feb 10, 2026HK inno.N Corporation announced that they will report Q4, 2025 results on Feb 10, 2026お知らせ • Jul 25HK inno.N Corporation to Report Q2, 2025 Results on Jul 30, 2025HK inno.N Corporation announced that they will report Q2, 2025 results on Jul 30, 2025New Risk • Apr 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Apr 22HK inno.N Corporation to Report Q1, 2025 Results on Apr 28, 2025HK inno.N Corporation announced that they will report Q1, 2025 results on Apr 28, 2025Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Executive Director Geun-Seok Song was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 13HK inno.N Corporation, Annual General Meeting, Mar 26, 2025HK inno.N Corporation, Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 239, osongsaengmyeong 2-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Koreaお知らせ • Mar 12598 Announces Annual DividendHK inno.N Corporation announced Annual dividend of KRW 350.0000 per share, ex-date on March 28, 2025 and record date on March 31, 2025.お知らせ • Oct 30HK inno.N Corporation to Report Q3, 2024 Results on Oct 30, 2024HK inno.N Corporation announced that they will report Q3, 2024 results on Oct 30, 2024Major Estimate Revision • May 03Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from ₩3,012 to ₩2,574 per share. Revenue forecast steady at ₩917.8m. Net income forecast to grow 11% next year vs 17% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩53,750 unchanged from last update. Share price was steady at ₩39,150 over the past week.Major Estimate Revision • Apr 14Consensus EPS estimates increase by 19%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩2,573 to ₩3,050. Revenue forecast steady at ₩918.9m. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩53,750. Share price fell 4.4% to ₩35,150 over the past week.お知らせ • Mar 14HK inno.N Corporation, Annual General Meeting, Mar 28, 2024HK inno.N Corporation, Annual General Meeting, Mar 28, 2024, at 09:01 Korea Standard Time.Upcoming Dividend • Dec 20Upcoming dividend of ₩320 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.1%).お知らせ • Jul 26HK inno.N Corporation to Report Q2, 2023 Results on Aug 01, 2023HK inno.N Corporation announced that they will report Q2, 2023 results on Aug 01, 2023Board Change • Jun 30High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Executive Chairman, CEO & President Dal-Won Kwak is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Major Estimate Revision • Apr 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩896.1m to ₩865.0m. EPS estimate also fell from ₩1,648 per share to ₩1,326 per share. Net income forecast to shrink 4.9% next year vs 39% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target broadly unchanged at ₩49,857. Share price was steady at ₩35,250 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩320 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).Price Target Changed • Nov 16Price target decreased to ₩52,500Down from ₩58,000, the current price target is an average from 8 analysts. New target price is 38% above last closing price of ₩38,100. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,458 for next year compared to ₩849 last year.Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₩50,100, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 18x in the Pharmaceuticals industry in South Korea.Major Estimate Revision • May 13Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩831.5m to ₩820.0m. EPS estimate also fell from ₩1,423 per share to ₩1,277 per share. Net income forecast to grow 49% next year vs 14% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩58,000 to ₩53,800. Share price was steady at ₩39,450 over the past week.業績と収益の成長予測KOSDAQ:A195940 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,242,332125,752156,300189,4331012/31/20271,190,237113,380141,900159,3361212/31/20261,091,91498,557145,867152,110712/31/20251,063,64977,51886,160133,4201012/31/2024911,19363,73571,456112,9501312/31/2023827,22547,06558,60078,256109/30/2022839,62741,49114,55642,613N/A6/30/2022830,09534,8074,15430,706N/A3/31/2022763,16020,425-5,79711,201N/A12/31/2021769,78621,345-4,70126,796N/A9/30/2021743,84528,39118,59367,922N/A6/30/2021706,48232,0165,75083,515N/A3/31/2021652,47733,123-17,68067,594N/A12/31/2020598,44727,897-39,48354,106N/A9/30/2020559,66920,597-42,55136,523N/A6/30/2020550,29213,822-34,26032,044N/A3/31/2020546,46514,10520,65785,280N/A12/31/2019539,90813,21755,902103,074N/A9/30/2019526,28828,68341,16579,366N/A6/30/2019508,36422,21010,92237,602N/A3/31/2019499,10835,832-98117,548N/A12/31/2018490,70047,74311,37321,757N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A195940の予測収益成長率 (年間17.8% ) は 貯蓄率 ( 3.1% ) を上回っています。収益対市場: A195940の収益 ( 17.8% ) KR市場 ( 31.9% ) よりも低い成長が予測されています。高成長収益: A195940の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: A195940の収益 ( 6.5% ) KR市場 ( 16% ) よりも低い成長が予測されています。高い収益成長: A195940の収益 ( 6.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A195940の 自己資本利益率 は、3年後には低くなると予測されています ( 5.8 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/22 21:01終値2026/07/22 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HK inno.N Corporation 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Dae Woong YooBookook Securities Co. LtdJisoo LeeDAOL Investment & Securities Co., Ltd.Myung Sun LeeDB Financial Investment Co. Ltd.14 その他のアナリストを表示
Major Estimate Revision • May 03Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from ₩3,012 to ₩2,574 per share. Revenue forecast steady at ₩917.8m. Net income forecast to grow 11% next year vs 17% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩53,750 unchanged from last update. Share price was steady at ₩39,150 over the past week.
Major Estimate Revision • Apr 14Consensus EPS estimates increase by 19%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩2,573 to ₩3,050. Revenue forecast steady at ₩918.9m. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩53,750. Share price fell 4.4% to ₩35,150 over the past week.
Major Estimate Revision • Apr 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩896.1m to ₩865.0m. EPS estimate also fell from ₩1,648 per share to ₩1,326 per share. Net income forecast to shrink 4.9% next year vs 39% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target broadly unchanged at ₩49,857. Share price was steady at ₩35,250 over the past week.
Price Target Changed • Nov 16Price target decreased to ₩52,500Down from ₩58,000, the current price target is an average from 8 analysts. New target price is 38% above last closing price of ₩38,100. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,458 for next year compared to ₩849 last year.
Major Estimate Revision • May 13Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩831.5m to ₩820.0m. EPS estimate also fell from ₩1,423 per share to ₩1,277 per share. Net income forecast to grow 49% next year vs 14% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩58,000 to ₩53,800. Share price was steady at ₩39,450 over the past week.
お知らせ • Apr 23HK inno.N Corporation to Report Q1, 2026 Results on Apr 28, 2026HK inno.N Corporation announced that they will report Q1, 2026 results on Apr 28, 2026
Board Change • Apr 22Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Chairman of the Board Yeo-Won Son was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Declared Dividend • Mar 12Dividend of ₩410 announcedShareholders will receive a dividend of ₩410. Ex-date: 25th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.8%, which is lower than the industry average of 1.1%. Sustainability & Growth The dividend has increased by an average of 2.3% per year over the past 4 years and payments have been stable during that time.
お知らせ • Mar 12HK inno.N Corporation, Annual General Meeting, Mar 26, 2026HK inno.N Corporation, Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 178, osongsaengmyeong-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea
お知らせ • Feb 11HK inno.N Corporation to Report Q4, 2025 Results on Feb 10, 2026HK inno.N Corporation announced that they will report Q4, 2025 results on Feb 10, 2026
お知らせ • Jul 25HK inno.N Corporation to Report Q2, 2025 Results on Jul 30, 2025HK inno.N Corporation announced that they will report Q2, 2025 results on Jul 30, 2025
New Risk • Apr 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Apr 22HK inno.N Corporation to Report Q1, 2025 Results on Apr 28, 2025HK inno.N Corporation announced that they will report Q1, 2025 results on Apr 28, 2025
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Executive Director Geun-Seok Song was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 13HK inno.N Corporation, Annual General Meeting, Mar 26, 2025HK inno.N Corporation, Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 239, osongsaengmyeong 2-ro, heungdeok-gu, chungcheongbuk-do, cheongju South Korea
お知らせ • Mar 12598 Announces Annual DividendHK inno.N Corporation announced Annual dividend of KRW 350.0000 per share, ex-date on March 28, 2025 and record date on March 31, 2025.
お知らせ • Oct 30HK inno.N Corporation to Report Q3, 2024 Results on Oct 30, 2024HK inno.N Corporation announced that they will report Q3, 2024 results on Oct 30, 2024
Major Estimate Revision • May 03Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from ₩3,012 to ₩2,574 per share. Revenue forecast steady at ₩917.8m. Net income forecast to grow 11% next year vs 17% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩53,750 unchanged from last update. Share price was steady at ₩39,150 over the past week.
Major Estimate Revision • Apr 14Consensus EPS estimates increase by 19%The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from ₩2,573 to ₩3,050. Revenue forecast steady at ₩918.9m. Net income forecast to grow 11% next year vs 16% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩53,750. Share price fell 4.4% to ₩35,150 over the past week.
お知らせ • Mar 14HK inno.N Corporation, Annual General Meeting, Mar 28, 2024HK inno.N Corporation, Annual General Meeting, Mar 28, 2024, at 09:01 Korea Standard Time.
Upcoming Dividend • Dec 20Upcoming dividend of ₩320 per share at 0.8% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.1%).
お知らせ • Jul 26HK inno.N Corporation to Report Q2, 2023 Results on Aug 01, 2023HK inno.N Corporation announced that they will report Q2, 2023 results on Aug 01, 2023
Board Change • Jun 30High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Executive Chairman, CEO & President Dal-Won Kwak is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Major Estimate Revision • Apr 13Consensus EPS estimates fall by 20%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩896.1m to ₩865.0m. EPS estimate also fell from ₩1,648 per share to ₩1,326 per share. Net income forecast to shrink 4.9% next year vs 39% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target broadly unchanged at ₩49,857. Share price was steady at ₩35,250 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩320 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%).
Price Target Changed • Nov 16Price target decreased to ₩52,500Down from ₩58,000, the current price target is an average from 8 analysts. New target price is 38% above last closing price of ₩38,100. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₩1,458 for next year compared to ₩849 last year.
Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₩50,100, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 18x in the Pharmaceuticals industry in South Korea.
Major Estimate Revision • May 13Consensus EPS estimates fall by 10%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩831.5m to ₩820.0m. EPS estimate also fell from ₩1,423 per share to ₩1,277 per share. Net income forecast to grow 49% next year vs 14% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩58,000 to ₩53,800. Share price was steady at ₩39,450 over the past week.